Maze Therapeutics, Inc. (MAZE)
NASDAQ: MAZE · Real-Time Price · USD
27.33
+0.41 (1.52%)
At close: Aug 3, 2026, 4:00 PM EDT
28.17
+0.84 (3.07%)
Pre-market: Aug 4, 2026, 4:07 AM EDT

Maze Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022
Period Ending
Aug '26 Dec '25 Dec '24 Dec '23 Dec '22
1,5132,044---
Market Cap Growth
131.79%----
Enterprise Value
1,2211,725000
Last Close Price
27.3341.43---
PB Ratio
3.955.76---
P/TBV Ratio
3.945.02---
Debt / Equity Ratio
0.170.05-0.07-0.12-0.10
Debt / EBITDA Ratio
--0.44--
Debt / FCF Ratio
--0.36--
Net Debt / Equity Ratio
-0.85-0.900.55-0.050.24
Net Debt / EBITDA Ratio
2.212.27-2.79-0.220.63
Net Debt / FCF Ratio
7.332.83-2.27-0.230.67
Asset Turnover
-01.0700
Quick Ratio
17.5415.169.521.794.81
Current Ratio
17.8815.509.762.095.11
Return on Equity (ROE)
-35.18%-598.95%-15.25%30.60%40.69%
Return on Assets (ROA)
-32.82%-44.82%36.10%-89.00%-74.04%
Return on Invested Capital (ROIC)
-308.53%-111.54%40.95%-106.91%-85.95%
Return on Capital Employed (ROCE)
-34.68%-48.08%41.87%-106.91%-85.95%
Buyback Yield / Dilution
-449.59%-1474.04%-19.33%-13.88%-
Total Shareholder Return
-449.59%-1474.04%-19.33%-13.88%-
SEC Filings: 10-K · 10-Q